• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

索拉非尼治疗期间出现肺气囊：一种罕见并发症的首例报告。

Pneumatocele during sorafenib therapy: first report of an unusual complication.

作者信息

Sangro Paloma, Bilbao Idoia, Fernández-Ros Nerea, Iñarrairaegui Mercedes, Zulueta Javier, Bilbao J I, Sangro Bruno

机构信息

Liver Unit, Department of Internal Medicine, Clínica Universidad de Navarra-IDISNA, Pamplona, Navarra, Spain.

Liver Unit, Department of Internal Medicine, Clínica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Navarra, Spain.

出版信息

Oncotarget. 2017 Dec 22;9(5):6652-6656. doi: 10.18632/oncotarget.23599. eCollection 2018 Jan 19.

DOI:10.18632/oncotarget.23599
PMID:29464101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5814241/
Abstract

Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement.

摘要

索拉非尼是一种多激酶抑制剂和血管内皮生长因子（VEGF）抑制剂，被批准用于治疗晚期肝细胞癌、肾细胞癌和分化型甲状腺癌患者。其最常见的副作用是乏力/疲劳、皮肤毒性、腹泻和动脉高血压。报告的呼吸道不良反应包括呼吸困难、咳嗽、胸腔积液和声音嘶哑。本报告的目的是首次描述两名接受索拉非尼治疗的患者发生肺气囊的情况。患者无呼吸道症状，且排除了其他诊断。原发肿瘤不同（胰腺神经内分泌肿瘤肝转移和肝细胞癌），但两名患者在开始使用索拉非尼之前分别在9个月和17个月接受了钇90放射性栓塞治疗。未发生并发症，停用索拉非尼后影像学有所改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/5cc17f9acc1b/oncotarget-09-6652-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/6fe29dbb03ef/oncotarget-09-6652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/a6dd56217f11/oncotarget-09-6652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/a0f7d577404e/oncotarget-09-6652-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/5cc17f9acc1b/oncotarget-09-6652-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/6fe29dbb03ef/oncotarget-09-6652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/a6dd56217f11/oncotarget-09-6652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/a0f7d577404e/oncotarget-09-6652-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f49a/5814241/5cc17f9acc1b/oncotarget-09-6652-g004.jpg

相似文献

1
Pneumatocele during sorafenib therapy: first report of an unusual complication.索拉非尼治疗期间出现肺气囊：一种罕见并发症的首例报告。
Oncotarget. 2017 Dec 22;9(5):6652-6656. doi: 10.18632/oncotarget.23599. eCollection 2018 Jan 19.
2
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.动脉内注射TheraSphere钇-90玻璃微球治疗不可切除肝细胞癌患者：STOP-HCC 3期随机对照试验方案
JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.
3
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.放射性栓塞联合索拉非尼治疗晚期肝细胞癌的安全性和毒性：欧洲多中心试验 SORAMIC 的分析。
Liver Int. 2015 Feb;35(2):620-6. doi: 10.1111/liv.12622. Epub 2014 Jul 8.
4
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.治疗消化系统肿瘤的索拉非尼、舒尼替尼和伊马替尼的不良反应。
Thorac Cancer. 2018 May;9(5):542-547. doi: 10.1111/1759-7714.12608. Epub 2018 Mar 25.
5
Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.索拉非尼与钇-90放射性栓塞联合治疗晚期肝细胞癌
Curr Oncol. 2016 Oct;23(5):e472-e480. doi: 10.3747/co.23.2827. Epub 2016 Oct 25.
6
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.索拉非尼治疗日本局部晚期或转移性甲状腺髓样癌和间变性甲状腺癌患者。
Thyroid. 2017 Sep;27(9):1142-1148. doi: 10.1089/thy.2016.0621. Epub 2017 Jul 24.
7
Sorafenib: a review of its use in advanced hepatocellular carcinoma.索拉非尼：其在晚期肝细胞癌中的应用综述
Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006.
8
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
9
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.索拉非尼在放射性碘难治性甲状腺癌患者中的安全性和耐受性。
Endocr Relat Cancer. 2015 Dec;22(6):877-87. doi: 10.1530/ERC-15-0252.
10
Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib.钇-90 放射性栓塞治疗索拉非尼治疗后肝细胞癌患者。
Front Oncol. 2013 Dec 30;3:323. doi: 10.3389/fonc.2013.00323. eCollection 2013.

引用本文的文献

1
Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.接受帕唑帕尼治疗的软组织肿瘤患者气胸的不同模式：病例系列分析。
PLoS One. 2021 Jul 16;16(7):e0254866. doi: 10.1371/journal.pone.0254866. eCollection 2021.

本文引用的文献

1
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.索拉非尼相关药物性肺损伤：日本全患者上市后监测分析。
Int J Clin Oncol. 2013 Aug;18(4):743-9. doi: 10.1007/s10147-012-0438-0. Epub 2012 Jun 30.
2
Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.钇-90 放射性栓塞后放射性肺炎：病例报告及文献复习。
J Vasc Interv Radiol. 2012 May;23(5):669-74. doi: 10.1016/j.jvir.2012.01.059.
3
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
索拉非尼通过阻断 STAT3 抑制肝癌的生长和转移。
World J Gastroenterol. 2011 Sep 14;17(34):3922-32. doi: 10.3748/wjg.v17.i34.3922.
4
Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.索拉非尼致肝癌患者间质性肺炎：1 例报告。
Gut Liver. 2010 Dec;4(4):543-6. doi: 10.5009/gnl.2010.4.4.543. Epub 2010 Dec 17.
5
STATs in cancer inflammation and immunity: a leading role for STAT3.信号转导和转录激活因子在癌症炎症与免疫中的作用：信号转导和转录激活因子3起主导作用
Nat Rev Cancer. 2009 Nov;9(11):798-809. doi: 10.1038/nrc2734.
6
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.索拉非尼通过激活磷酸酶“防破碎2”来抑制胆管癌细胞中的信号转导和转录激活因子3信号通路。
Hepatology. 2009 Dec;50(6):1861-70. doi: 10.1002/hep.23214.
7
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.索拉非尼抑制与髓母细胞瘤生长停滞和凋亡相关的信号转导及转录激活因子3信号通路。
Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
8
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.索拉非尼在人食管腺癌细胞中触发抗增殖和促凋亡信号。
Dig Dis Sci. 2008 Dec;53(12):3055-64. doi: 10.1007/s10620-008-0294-y. Epub 2008 May 30.
9
Necrotizing pneumonia complicated by early and late pneumatoceles.坏死性肺炎并发早期及晚期肺气囊。
Can Respir J. 2008 Apr;15(3):129-32. doi: 10.1155/2008/136708.
10
The hyper-IgE syndromes.高免疫球蛋白E综合征
Immunol Allergy Clin North Am. 2008 May;28(2):277-91, viii. doi: 10.1016/j.iac.2008.01.005.